RA-9 is a cell permeable and potent inhibitor of the ubiquitin-proteasome system (UPS) that targets deubiquitinating enzymes (DUB) without affecting 20S proteasome catalytic-core activity. Treatment with RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors。

C527 is a is a pan DUB enzyme inhibitor, with a high potency for the USP1/UAF1 complex (IC50=0.88 μM).

DUBs-IN-3 is a potent deubiquitinase enzyme inhibitor with IC50s of 3.1 μM for USP8, showing > 30 fold selectivity over USP7 (IC50 > 100 μM).

ML364 is an USP2 inhibitor.

FT671 is a potent and selective USP7 inhibitor with an IC50 of 52 nM and binds to the USP7 catalytic domain with a Kd of 65 nM.

IU1-47 is a potent USP14 inhibitor with IC50 value of 60nM.

SJB3-019A is a potent USP1 inhibitor, 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells with IC50 of 0.0781 μM.

HBX 19818 is a selective USP7 inhibitor with IC50 of 28.1 μM .

GNE-6640 is a selective inhibitor of ubiquitin specific protease-7 (USP7) (IC50 = 0.75 μM) that can induce tumor cell death and enhance the effect of chemotherapy drugs.

USP25/28 inhibitor AZ1 is a potent, selective and noncompetitive inhiibitor of both USP25 and USP28 with IC50 values of 0.7μM and 0.6μM, respectively.

GNE-6776 is selective ubiquitin specific protease-7 (USP7) inhibitor with IC50 of 1.34 μM through binding to acidic amino acid residues.

Auranofin is a proteasomal deubiquitinase inhibitor with inhibition of the proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than 20S proteasome, which is required for Auranofin-induced cytotoxicity. It selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients and by blocking NF-κB activation, Auranofin can attenuats the cardiac hypertrophy.

Capzimin shows > 5-fold selectivity for Rpn11 over the related JAMM proteases and > 2 logs selectivity over several other metalloenzymes.